- Home
- SKYT vs VERV Comparison
SKYT vs VERV Comparison
Compare SKYT & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYT
- VERV
- Stock Information
- Founded
- SKYT 1991
- VERV 2018
- Country
- SKYT United States
- VERV United States
- Employees
- SKYT N/A
- VERV N/A
- Industry
- SKYT Semiconductors
- VERV Medicinal Chemicals and Botanical Products
- Sector
- SKYT Technology
- VERV Health Care
- Exchange
- SKYT Nasdaq
- VERV Nasdaq
- Market Cap
- SKYT 560.4M
- VERV 475.0M
- IPO Year
- SKYT 2021
- VERV 2021
- Fundamental
- Price
- SKYT $11.76
- VERV $6.57
- Analyst Decision
- SKYT Strong Buy
- VERV Strong Buy
- Analyst Count
- SKYT 4
- VERV 4
- Target Price
- SKYT $12.75
- VERV $25.75
- AVG Volume (30 Days)
- SKYT 1.1M
- VERV 1.4M
- Earning Date
- SKYT 02-24-2025
- VERV 02-25-2025
- Dividend Yield
- SKYT N/A
- VERV N/A
- EPS Growth
- SKYT N/A
- VERV N/A
- EPS
- SKYT N/A
- VERV N/A
- Revenue
- SKYT $345,935,000.00
- VERV $24,396,000.00
- Revenue This Year
- SKYT $21.36
- VERV $97.47
- Revenue Next Year
- SKYT N/A
- VERV N/A
- P/E Ratio
- SKYT N/A
- VERV N/A
- Revenue Growth
- SKYT 26.89
- VERV 219.91
- 52 Week Low
- SKYT $5.63
- VERV $4.31
- 52 Week High
- SKYT $19.00
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- SKYT 47.98
- VERV 58.47
- Support Level
- SKYT $11.40
- VERV $5.32
- Resistance Level
- SKYT $12.44
- VERV $6.87
- Average True Range (ATR)
- SKYT 1.08
- VERV 0.53
- MACD
- SKYT -0.44
- VERV 0.05
- Stochastic Oscillator
- SKYT 12.91
- VERV 80.71
About SKYT SkyWater Technology Inc.
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.